In March 2020 , the reality of Covid-19 began to make itself felt in countries across the world . For governments , and for industry , the arrival of the virus initiated a race against the clock . Faced with a new and unpredictable enemy , they set to work on the production of a series of vaccines which , more than two years later , have saved countless lives across the globe .
But this progress wasn ’ t always a given . According to Rahul Singhvi , CEO at Resilience , a technologyfocused biomanufacturing company dedicated to broadening access to complex medicines and to protecting biopharmaceutical supply chains against disruption , one of the few upsides to come from Covid-19 has been a welcome jolt to a sector that had promised much , but failed to deliver . “ As biomedical science had taken off and given rise to incredible curative therapies , bio-manufacturing had failed to keep pace ,” he says , speaking to Manufacturing Today . “ During the pandemic , it became apparent that we needed to do something different , and better , to protect the world from biological threats .”
Founded in mid-2020 at the height of the pandemic , Resilience hopes to be that difference . The company ’ s vision is to revolutionize how medicines are made , funded , and scaled , working across five key ‘ modalities ’: biologics , cell therapy , gene therapy , nucleic acids , and vaccines . Resilience partners across these modalities with research and academic institutes , emerging biotech
“
During the pandemic , it became apparent
“ that we needed to do something different
or established pharmaceutical companies , and governments , providing access to its state-of-the-art equipment , shared lab space , and vast team of highly specialized industry experts . Through this collaboration , the company argues that it can help such partners identify where their own emerging discoveries might lead , be it the incubation of a new therapy , drug manufacturing technology , or process improvement project .
manufacturing-today . com 125